As of March 18, 2026, 10:13, the components of the CSI Medicine and Medical Device Innovation Index (931484) showed mixed performance, with Sanofi leading with a 6.11% increase, Haier Medical rising by 1.06%, and Nanwei Medical up by 0.35%; Aimeike led the decline. The latest price of the Medical Innovation ETF (516820) is 0.36 yuan.
In terms of liquidity, the Medical Innovation ETF had a turnover of 0.58% during the session, with a transaction volume of 10.6295 million yuan. Looking at a longer time frame, as of March 17, the average daily transaction volume of the Medical Innovation ETF over the past year was 51.0169 million yuan.
On the news front, on March 17, the National Medical Products Administration (NMPA) released an announcement regarding the publication of 26 industry standards for medical devices, including &#34;Bone Fusion Implant Devices Metal Bone Plates.&#34; Additionally, the NMPA recently approved the registration application for the innovative product of the implanted brain-machine interface hand movement compensation system by Boruikang Medical Technology (Shanghai) Co., Ltd., achieving the global first launch of brain-machine interface medical devices, marking the entry of the world's first invasive brain-machine interface medical device into the clinical application stage.
Kaiyuan Securities pointed out that as a future industry identified in the &#34;14th Five-Year Plan,&#34; the NMPA is allocating resources in product review and approval for brain-machine interfaces, conducting pre-review services for innovative products based on the principles of &#34;early intervention, one enterprise one policy, full guidance, and research-review linkage,&#34; effectively accelerating the product launch process and significantly enhancing the international competitiveness of China's high-end medical devices. The &#34;Brain-Machine Interface Future Industry Cultivation Action Plan (2025-2030)&#34; issued by Shanghai clearly states that by 2027, it aims to promote more than five invasive and semi-invasive products to complete clinical trials. With Boruikang taking the lead in breaking the deadlock, we believe that companies like Ladder Medical, Xinwei Medical, and Brain Tiger Technology are also expected to accelerate their clinical trial processes, strengthening the synergistic effects of the brain-machine interface industry cluster.
The Medical Innovation ETF closely tracks the CSI Medicine and Medical Device Innovation Index, which selects 30 publicly listed companies with good profitability, certain growth potential, and research and innovation capabilities from the pharmaceutical and healthcare industry as index samples, reflecting the overall performance of publicly listed securities in the pharmaceutical and medical device sectors that combine profitability and growth.
Data shows that as of February 27, 2026, the top ten weighted stocks in the CSI Medicine and Medical Device Innovation Index (931484) are WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, Pian Zai Huang, New Hope Liuhe, East China Medical, Kanglong Huacheng, Ailisi, and Dong'e Ejiao, with the top ten weighted stocks accounting for a total of 63.75%.
Risk Warning: Funds carry risks, and investment requires caution. The fund manager promises to manage and utilize fund assets based on the principles of honesty, credit, diligence, and responsibility, but does not guarantee that this fund will definitely make a profit, nor does it guarantee a minimum return. The fund manager reminds investors of the &#34;buyer bears the risk&#34; principle in fund investment; after making investment decisions, the investment risks arising from the fund's operating status and changes in net value are borne by the investors themselves. The past performance of the fund and its net value does not indicate its future performance, and the performance of other funds managed by the fund manager does not constitute a guarantee of this fund's performance
Investors purchasing funds may share in the profits generated by the fund's investments according to their held shares, but they may also bear the losses arising from the fund's investments. Investors should carefully read the &#34;Fund Contract,&#34; &#34;Prospectus,&#34; and other legal documents related to the fund, fully understand the risk-return characteristics and product features of this fund, and assess whether the fund aligns with their risk tolerance based on their investment objectives, investment horizon, investment experience, and asset status. They should make rational market judgments and exercise caution in making investment decisions. The relevant information in this material is sourced from publicly available materials deemed reliable by the fund manager, and the related opinions, assessments, and forecasts reflect current judgments that may change in the future. Any market opinions contained in this material are based on corresponding assumptions, and any assumptions may change at any time. The fund manager does not promise or guarantee that any predictive market opinions will necessarily be realized. The individual stocks mentioned in the material do not constitute investment recommendations or advice. The fluctuations in the secondary market of ETF funds do not represent the actual return rate of the fund; investors should pay attention to the risks of price volatility in the market

The National Medical Products Administration released 26 industry standards for medical devices, attracting attention to medical innovation ETFs. The constituents of the CSI Medicine and Medical Device Innovation Index showed mixed performance, with the latest quote for the medical innovation ETF at 0.36 yuan and an average daily trading volume of 51.0169 million yuan. The National Medical Products Administration approved the registration of BrainCo's brain-computer interface products, marking the entry of the world's first invasive brain-computer interface medical device into clinical application. Kaiyuan Securities pointed out that the brain-computer interface industry will accelerate its development, and related companies are expected to speed up the clinical trial process

腾讯新闻 - 财经

iShares US Pharma

SPDR Pharmac

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

E Fund CSI 300 Health Care ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

GF Fund CSI Medical Service ETF

Invesco Pharmaceuticals ETF

Penghua CSI Health Care Index Fund(LOF)-A

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Medical Service ETF

GF CSI All Share Health Care ETF

VanEck Pharmaceutical ETF

China Merchants CSI Biotechnology Theme ETF

The Drug Administration announced 26 industry standards for medical devices, and medical innovation ETFs are receiving significant attention